<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The deregulation of paxillin (PXN) has been involved in the progression and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of different <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>miR-137 is frequently suppressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PXN is predicted to be a direct target of miR-137 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>On this basis, we hypothesized that overexpression of PXN induced by suppression of miR-137 may promote <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and predicts poor prognosis </plain></SENT>
<SENT sid="4" pm="."><plain>We detected the expression of PXN and miR-137 in clinical <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues by immunohistochemical analysis and real-time PCR, positive PXN staining was observed in 198 of the 247 (80.1%) cases, whereas no or weak PXN staining was observed in the adjacent non-cancerous area </plain></SENT>
<SENT sid="5" pm="."><plain>Higher level of PXN <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) and lower level of miR-137 was observed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> tissues than adjacent non-cancerous tissues </plain></SENT>
<SENT sid="6" pm="."><plain>High expression of PXN and low expression of miR-137 was associated with aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> phenotype and adverse prognosis </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, the expression of PXN was negatively correlated with miR-137 expression </plain></SENT>
<SENT sid="8" pm="."><plain>A dual-luciferase reporter gene assay validated that PXN was a direct target of miR-137 </plain></SENT>
<SENT sid="9" pm="."><plain>The use of miR-137 mimics or inhibitor could decrease or increase PXN <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="10" pm="."><plain>Knockdown of PXN or ectopic expression of miR-137 could markedly inhibit cell proliferation, migration and invasion in vitro and repress <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>Taken together, these results demonstrated that overexpression of PXN induced by suppression of miR-137 promotes <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and could serve as an independent prognostic indicator in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>